The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.
 
Oleg Gluz
No Relationships to Disclose
 
Ulrike Nitz
Research Funding - Bayer (Inst); Celgene (Inst); Teva (Inst)
 
Matthias Christgen
No Relationships to Disclose
 
Eva-Maria Grischke
No Relationships to Disclose
 
Helmut Forstbauer
No Relationships to Disclose
 
Michael Wilhelm Braun
No Relationships to Disclose
 
Mathias Warm
No Relationships to Disclose
 
Christoph Uleer
No Relationships to Disclose
 
Bahriye Aktas
No Relationships to Disclose
 
Claudia Schumacher
No Relationships to Disclose
 
John Hackmann
No Relationships to Disclose
 
Nikola Bangemann
No Relationships to Disclose
 
Peter Staib
No Relationships to Disclose
 
Christoph Lindner
No Relationships to Disclose
 
Sherko Kummel
No Relationships to Disclose
 
Cornelia Liedtke
Honoraria - Celgene
 
Ronald E. Kates
Honoraria - Amgen (I); Celgene (I); NanoString Technologies (I); Novartis (I); Pfizer (I); Roche Pharma AG (I)
Consulting or Advisory Role - AstraZeneca (I); Celgene (I); Genomic Health (I); Novartis (I); Roche Pharma AG (I); Wilex (I)
Research Funding - Boehringer Ingelheim (I); Novartis (I); Pfizer (I); Roche Pharma AG (I)
 
Rachel Wuerstlein
No Relationships to Disclose
 
Hans Heinrich Kreipe
Honoraria - AstraZeneca; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Roche Pharma AG
Expert Testimony - AstraZeneca; Roche Pharma AG
 
Nadia Harbeck
Honoraria - Amgen; Celgene; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Celgene; Genomic Health; Novartis; Roche/Genentech; Sandoz; Wilex
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)